ZBRNCT05914662
Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM
StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
At risk: Primary completion moved 1 year 8 months later.
See at-risk trials from Institute of Hematology & Blood Diseases Hospital, China
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Mar 15, 2025 to Nov 15, 2026 Show 7 more changesShow less
- Start date pushed from Feb 15, 2023 to Jun 30, 2023
- Eligibility criteria expanded, about 5 words
- Trial status changed: Unknown → Active, Not Recruiting
- Enrollment increased: 42 → 48 participants
- Study completion pushed from Dec 15, 2025 to Dec 15, 2026
- Site details revised
- Publications: details revised at 9 of 11 entries
- Minor Changed Registry marked status Unknown; last known: Recruiting
- Minor Trial status: Recruiting to Unknown
- Enrollment target: 30 to 42
- Secondary endpoints: details revised at 1 of 7 entries
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Best combined complete response (CR) and very good partial response (VGPR)
Timeframe: up to the end of 12 cycles of treatment(each cycle is 28 days)
Secondary (7)
Overall objective response rate (ORR), complete response rate(CR),major response rate(MR)
Time to response, time to best response
Overall survival(OS)
Progression free survival(PFS)
Duration of Response
Show 2 moreShow less
Time to Next Treatment
Safety of treatment regimens
Arms and interventions
Zanubrutinib, bendamustine, rituximab combination therapy GroupExperimental
Patients were treated with ZBR regimen for 6 cycles, followed by zanubrutinib monotherapy for an additional 6 months.
Drugs: Zanubrutinib, Bendamustine and Rituximab
Sites
1 site in 1 country
- Institute of Hematology & Blood Diseases HospitalTianjin, Tianjin Municipality, China